205 related articles for article (PubMed ID: 8549651)
1. Modulation of sensitivity to transforming growth factor-beta 1 (TGF-beta 1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone.
Kim IY; Zelner DJ; Sensibar JA; Ahn HJ; Park L; Kim JH; Lee C
Exp Cell Res; 1996 Jan; 222(1):103-10. PubMed ID: 8549651
[TBL] [Abstract][Full Text] [Related]
2. The conventional transforming growth factor-beta (TGF-beta) receptor type I is not required for TGF-beta 1 signaling in a human prostate cancer cell line, LNCaP.
Kim IY; Zelner DJ; Lee C
Exp Cell Res; 1998 May; 241(1):151-60. PubMed ID: 9633523
[TBL] [Abstract][Full Text] [Related]
3. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
Guo Y; Kyprianou N
Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
[TBL] [Abstract][Full Text] [Related]
5. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells.
Kim IY; Ahn HJ; Zelner DJ; Shaw JW; Sensibar JA; Kim JH; Kato M; Lee C
Cancer Res; 1996 Jan; 56(1):44-8. PubMed ID: 8548772
[TBL] [Abstract][Full Text] [Related]
6. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Guo Y; Kyprianou N
Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP.
Kim IY; Kim JH; Zelner DJ; Ahn HJ; Sensibar JA; Lee C
Endocrinology; 1996 Mar; 137(3):991-9. PubMed ID: 8603613
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells.
Evangelou A; Jindal SK; Brown TJ; Letarte M
Cancer Res; 2000 Feb; 60(4):929-35. PubMed ID: 10706107
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-beta receptors in human cancer cell lines: analysis of transcript, protein and proliferation.
Jakowlew SB; Moody TW; Mariano JM
Anticancer Res; 1997; 17(3C):1849-60. PubMed ID: 9216635
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells.
Bruckheimer EM; Kyprianou N
Prostate; 2002 Oct; 53(2):133-42. PubMed ID: 12242728
[TBL] [Abstract][Full Text] [Related]
11. Stromal cells of the human prostate: initial isolation and characterization.
Kassen A; Sutkowski DM; Ahn H; Sensibar JA; Kozlowski JM; Lee C
Prostate; 1996 Feb; 28(2):89-97. PubMed ID: 8604397
[TBL] [Abstract][Full Text] [Related]
12. The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells.
Lucia MS; Sporn MB; Roberts AB; Stewart LV; Danielpour D
J Cell Physiol; 1998 May; 175(2):184-92. PubMed ID: 9525477
[TBL] [Abstract][Full Text] [Related]
13. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer.
van der Poel HG
Eur Urol; 2005 Dec; 48(6):1051-8. PubMed ID: 16257107
[TBL] [Abstract][Full Text] [Related]
15. Bone morphogenetic protein-2 induces hypophosphorylation of Rb protein and repression of E2F in androgen-treated LNCaP human prostate cancer cells.
Tomari K; Kumagai T; Shimizu T; Takeda K
Int J Mol Med; 2005 Feb; 15(2):253-8. PubMed ID: 15647840
[TBL] [Abstract][Full Text] [Related]
16. Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line.
Hofbauer LC; Hicok KC; Khosla S
J Cell Biochem; 1998 Oct; 71(1):96-108. PubMed ID: 9736458
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.
Osada H; Tatematsu Y; Masuda A; Saito T; Sugiyama M; Yanagisawa K; Takahashi T
Cancer Res; 2001 Nov; 61(22):8331-9. PubMed ID: 11719467
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
19. Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells.
Evangelou A; Letarte M; Jurisica I; Sultan M; Murphy KJ; Rosen B; Brown TJ
Cancer Res; 2003 May; 63(10):2416-24. PubMed ID: 12750261
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
Song K; Cornelius SC; Danielpour D
Cancer Res; 2003 Aug; 63(15):4358-67. PubMed ID: 12907605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
